Karyopharm Therapeutics Inc. (KPTI)

NASDAQ: KPTI · IEX Real-Time Price · USD

1.090

0.00 (0.00%)

At close: Apr 24, 2024, 4:00 PM

1.100

+0.010 (0.92%)

Pre-market: Apr 25, 2024, 8:46 AM EDT

Karyopharm Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2011
Cash & Equivalents	53.19	136.89	197.45	89.12	130.69	118.74	69.49	50.14	58.84	151.01	Upgrade
Short-Term Investments	139.21	142.78	38.16	163.32	133.1	210.18	77.47	79.89	117.28	55.12	Upgrade
Cash & Cash Equivalents	192.4	279.66	235.6	252.44	263.79	328.92	146.96	130.03	176.12	206.12	Upgrade
Cash Growth	-31.20%	18.70%	-6.67%	-4.30%	-19.80%	123.81%	13.02%	-26.17%	-14.56%	32.15%	Upgrade
Receivables	26.96	47.09	22.5	12.88	7.86	0	0	0	0	0	Upgrade
Inventory	3.04	4.22	4.11	2.64	0.35	0	0	0	0	0	Upgrade
Other Current Assets	11.51	19.19	13.4	8.56	6.58	5.7	1.46	1.61	1.49	1.63	Upgrade
Total Current Assets	233.92	350.16	275.61	276.53	278.57	334.61	148.42	131.64	177.6	207.75	Upgrade
Property, Plant & Equipment	4.88	7.38	9.56	11.58	13.66	3.86	2.19	2.84	3.48	2.75	Upgrade
Long-Term Investments	0	0	0	24.22	2.02	2	29.4	45.43	33.88	8.66	Upgrade
Other Long-Term Assets	1.64	0.63	20.14	0.72	0.71	0.72	0.29	0.48	0.48	1.17	Upgrade
Total Long-Term Assets	6.52	8.01	29.7	36.52	16.39	6.58	31.87	48.75	37.84	12.59	Upgrade
Total Assets	240.44	358.17	305.31	313.05	294.96	341.19	180.29	180.39	215.44	220.34	Upgrade
Accounts Payable	3.12	2.77	1.6	4.45	0.99	4.33	5.67	4.75	3.81	6.29	Upgrade
Deferred Revenue	0	0	0	0.3	4.53	13.89	21.92	0	0	0	Upgrade
Current Debt	3.31	2.87	2.32	1.92	1.65	0	0	0	0	0	Upgrade
Other Current Liabilities	63.05	60.26	69.8	53.54	39.19	28.68	21.88	11.73	11.32	6.01	Upgrade
Total Current Liabilities	69.48	65.91	73.72	60.2	46.35	46.9	49.47	16.48	15.13	12.3	Upgrade
Long-Term Debt	173.71	176.2	178.26	129.21	123.06	102.66	0	0	0	0	Upgrade
Other Long-Term Liabilities	133.46	132.72	133	73.09	75.78	8.45	1.36	1.67	1.95	1.24	Upgrade
Total Long-Term Liabilities	307.17	308.92	311.26	202.3	198.84	111.12	1.36	1.67	1.95	1.24	Upgrade
Total Liabilities	376.64	374.83	384.98	262.5	245.19	158.02	50.83	18.14	17.08	13.54	Upgrade
Total Debt	177.02	179.07	180.58	131.13	124.71	102.66	0	0	0	0	Upgrade
Debt Growth	-1.15%	-0.83%	37.71%	5.15%	21.47%	-	-	-	-	-	Upgrade
Retained Earnings	-1,487.04	-1,343.94	-1,178.65	-1,069.61	-873.34	-673.75	-495.34	-366.1	-256.53	-138.35	Upgrade
Comprehensive Income	-0.16	-0.64	0.19	0.52	-0.04	-0.24	-0.22	-0.27	-0.28	-0.03	Upgrade
Shareholders' Equity	-136.21	-16.66	-79.67	50.55	49.77	183.17	129.46	162.24	198.37	206.79	Upgrade
Net Cash / Debt	15.39	100.59	55.02	121.31	139.08	226.25	146.96	130.03	176.12	206.12	Upgrade
Net Cash / Debt Growth	-84.70%	82.81%	-54.64%	-12.78%	-38.53%	53.96%	13.02%	-26.17%	-14.56%	32.15%	Upgrade
Net Cash Per Share	0.13	1.23	0.73	1.68	2.24	3.98	3.20	3.47	4.94	6.62	Upgrade
Working Capital	164.44	284.25	201.89	216.33	232.22	287.71	98.96	115.16	162.47	195.45	Upgrade
Book Value Per Share	-1.19	-0.20	-1.06	0.70	0.80	3.23	2.82	4.32	5.57	6.64	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).